Developmental toxicity of naproxen;Toksyczność rozwojowa naproksenu

Polski Merkuriusz Lekarski

Volumn 23, Issue 134, 2007, Pages 155-158

  Burdan, Franciszek ^a   Sykut, Justyna ^a   Przybylski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

COX 1; COX 2; Fetus; Nonsteroidal antiinflammatory drug; Pregnancy

Indexed keywords

NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ANIMAL; CONGENITAL MALFORMATION; DUCTUS ARTERIOSUS; DYSMENORRHEA; FEMALE; FETOMATERNAL TRANSFUSION; HEART SEPTUM DEFECT; HUMAN; MALE; MOUSE; NEWBORN; OSTEOARTHRITIS; PATHOLOGY; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PRENATAL EXPOSURE; RABBIT; RAT; REVIEW; SPECIES DIFFERENCE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS; DYSMENORRHEA; FEMALE; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; MICE; NAPROXEN; OSTEOARTHRITIS; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RABBITS; RATS; SPECIES SPECIFICITY;

EID: 34548591805     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Alano M.A., Ngougmna E., Ostre E. i wsp.: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics, 2001, 107, 519-523.
2. Amadio P.: Peripherally acting analgesics. Am. J. Med., 1984, 17-26.
3. Briggs G.G., Freeman R.K., Yaffe SJ.: Drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. Williams&Wilkins, Baltimore, 1998, 524-525.
4. Burdan F.: Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI) WUBR Wistar rats - DFU and piroxicam study. Toxicology, 2005, 211, 12-25.
5. Burdan F.: Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats. Hum. Exp. Toxicol. 2002, 21, 25-31.
6. Burdan F., Korobowicz A.: Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy. Pol. Merk. Lek., 2003, 14, 348-351.
7. Burdan F., Chalas A., Szumilo J.: Cyclooxygenase and prostanoids - biological implications. Postepy Hig. Med., 2006, 60, 129-141.
8. Burdan F., Szumilo J., Dudka J. i wsp.: Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz. J. Med. Biol. Res., 2006, 39, 925-934.
9. Chahoud I., Ligensa A., Dietzel L. i wsp.: Correlation between maternal toxicity and embryo:fetal effects. Reprod. Toxicol., 1999, 13, 375-381.
10. Cleves M.A., Savell V.H. Jr, Raj S. i wsp.: Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res. A Clin. Mol. Teratol., 2004, 70, 107-113.
11. Crofford L.J., Wilder R.L., Ristimaki A.P. i wsp.: Cyklooksygenase-1 and -2 expression in rheumatoid synovial tissues. Effect of interleukin-1 beta, phorbal ester, and corticosteroid. J. Clin. Invest., 1994, 93, 1095-1101.
12. Ericson A., Kallen BA.: Nonsteroidal anti-inflammatory drugs in early pregnency. Reprod. Toxicol., 2001, 15, 371-375.
13. Gemzell-Danielsson K., Hamburg M.: The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations. Hum. Reprod. 1994, 9, 1626-1630.
14. Gupta U., Thomas K.J., Datta H. i wsp.: Effect of ibuprofen and naproxen on implantation and pregnancy in rat. Indian J. Exp. Biol., 1984, 22, 282-283.
15. Hallesy D.W., Short L.D., Hill R.: Comparative toxicology of naproxen. Scand. J. Rheumatol., 1973, 3, supl. 2, 20-28.
16. Jaszczak S.E.: Anovulatory luteal cycles in primates. Contraception, 1983, 27, 505-514.
17. Kallen B.: Maternal drug use and infant cleft lip:palate with special reference to corticoids. Cleft Palate Craniofac. J., 2003, 40, 624-628.
18. Kallen B., Otterblod-Olausson P.: Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod. Toxicol., 2003, 17, 255-261.
19. Koklu E., Gurgoze M., Akgun H. i wsp.: Renal tubular dysgenesis with atypical histology and in-utero exposure to naproxen sodium. Ann. Trop. Paediatr., 2006, 26(3), 241-245.
20. Kostowski W., Herman Z. (red.), Farmakologia - podstawy farmakoterapii. PZWL. Warszawa. 2005, 234-244.
21. Kuhn D.C., Stuart M.J.: Cyclooxygenase inhibition reduces placental transfer. Reversal by carbacydin. Am. J. Obstet. Gynecol., 1987, 157, 194-198.
22. Laneuville O., Breuer O.K., Dewitt D.L. i wsp.: Differential inhibition of human prostaglandin endoperoxide H synthase- and -2 by nonsteroidal antiinflammatory drugs. J. Pharmacol. Exp. Ther., 1994, 271, 927-934.
23. Levin D.L.: Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin. Perinatol., 1980, 4, 35-44.
24. Makila U.M., Kokkonen E., Viinikka L. i wsp.: Differential inhibition of fetal vascular prostacyclin and platelet thromboxane synthesis by nonsteroidal antiinflammatory drugs in humans. Prostoglandins, 1993, 25, 39-46.
25. Mitchell J.A., Akarasereenont P., Thiemermann C. i wsp.: Selectivity of nonsteoroidal antiinflammatory drugs as inhibitors of constitutive and inductible cyclooxygenase. Proc. Natal. Acad. Sci. USA, 1993, 99, 11693-11697.
26. Montenegro M.A., Palomino H.: Induction of clef palate in mice by inhibitors of prostaglandin synthesis. J. Craniofac Genet Del. Biol., 1990, 10, 83-94.
27. Ofori B., Oraichi D., Blais L. i wsp.: Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs, a nested case-control study. Birth Defects Res. B Dev. Reprod. Toxicol., 2006, 77, 268-279.
28. Ostensen M., Khamashta M., Lockshin M. i wsp.: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther., 2006, 8, 209.
29. Powell J.G. Jr, Cochrane R.L.: The effects of a number of non-steroidal anti-inflammatory compounds on parturition in the rat. Prostaglandins, 1982, 23, 469-488.
30. Produkt information. Naprosyn. Syntez Laboratories, 1993.
31. Radestad A., Bygdeman M.: Cervical softening with mifepristone (RU 486) after pretreatment with naproxen. A double-blind randomized study. Contraception, 1992, 45, 221-227.
32. Rudolph A.M.: The effects of nonsteroidal anti-inflammatory compounds on fetal circulation and pulmonary function. Obstet Gynecol 1981; 58(Suppl), 63-67.
33. Schonbeck U., Sukhova O.K., Graber P. i wsp.: Augumented expression of cyklooxygenase-2 in human atherosclerotic lesion. Am. J. Pathol., 1999, 155, 1281-191.
34. Siu S.S., Yeung J.H., Lau T.K.: An in-vivo study on placental transfer of naproxen in early human pregnancy. Hum. Reprod., 2002, 17, 1056-1059.
35. Ueno K., Masumura H., Kawamoto H. i wsp.: Effects of ketoprofen and other drugs on release of prostaglandins from uterus of rabbits in perinatal period. Res. Commun. Chem. Pathol. Pharmacol., 1988, 59, 141-144.
36. Ueno K., Masumura H., Kawamoto H. i wsp.: Effects of ketoprofen on release of pmstaglandin F2 alpha from uterus of rat in perinatal period. Res. Commun. Chem. Pathol. Pharmacol., 1987, 58, 173-182.
37. van der Heijden B., Gubler M.C.: Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory drugs. Pediatr. Nephrol., 1995, 9, 675-676.
38. Wallace J.L.: Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology, 1997, 112, 1000-1016.
39. Wilkinnson A.R.: Naproxen levels in preterm infants after maternal treatment. Lancet, 1980, 8194, 591-592.
40. Zanagnolo V., Dharmarajan A., Endo K. i wsp.: Effects of acetylsalicylic acid (aspirin) and naproksen sodium (naproksen) on ovulation, prostaglandin, and progesterone production in the rabbit. Fertil. Steril., 1996, 65, 1036-1043.